Depression and Suicide Risk in Patients with Schizophrenia during the Treatment by Second Generation Antipsychotic Agents: A Mini-Review

키워드

참고문헌 (57)

1. Miller AL, "The Texas Medication Algorithm", pp.500~508 (2003)
2. Kinon BJ, "Mechanisms of action of atypical antipsychotic drugs: a critical analysis", 124, pp.2~34 (1996)
3. "Miles CP. Conditions predisposing to suicide", pp.231~246
4. "Roth S. The seemingly ubiquitous depresion following acute schizophrenic episodes a neglected area of clinical discusion. Am J Psychiatry 1970", pp.51~58
5. "Siris SG. Diagnosis of secondary depression in schizophrenia implications for DSM-IV. Schizophr Bul 1991", pp.75~98
6. Siris SG, "Depression in schizophrenia: perspective in the era of Atypical antipsychotic agents", 157, pp.1379~1389 (2000)
7. "Kaneda Y. The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schi-zophrenia. Clin Neuropharmacol 203"
8. Meltzer HY, "Treatment of suicidality in schizophrenia", 932, pp.44~58 (2001)
9. Kulhara P, "Negative and depressive symptoms in schizo-phrenia", pp.207~211
10. Kay SR, "Plutchik R. Multivantaged ases-ment of depression in schizophrenia. Psychiatry Res 1992"
11. Barnes TR, "Patel M. The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry 1989", pp.486~491
12. Kaneda Y, "Depresive Symptoms in Medicated Chronic Schizophrenics", 2, pp.1~12 (1999)
13. Norman RM, "Mala AK. Correlations over time betwen dys-phoric mod and symptomatology in schizophrenia. Compr Psy-chiatry 1994", pp.34~38
14. McAdams LA, "et al. Depresive symptoms in schizophrenia. Am J Psychi-atry 199", pp.1736~1743
15. "Hirsch SR. Depresion revealed in schizophrenia. Br J Psy-chiatry 1982", pp.421~423
16. Knights A, "Hirsch SR. Revealed Depression and drug treat-ment for schizophrenia. Arch Gen Psychiatry 1981", pp.806~81
17. Van Puten T, "May RP. Akinetic depression in schizophrenia. Arch Gen Psychiatry 1978", pp.101~107
18. Bressan RA, "Ty-pical antipsychotic drugs -- D(2) receptor occupancy and de-pressive symptoms in schizophrenia", 56, pp.31~36 (2002)
19. "Galdi J. The causality of depression in schizophrenia. Br J Psy-chiatry 1983", pp.621~624
20. Kapur S, "Mann JJ. Role of the dopaminergic system in depres-sion. Biol Psychiatry 1992", pp.1~17
21. Prosser ES, "and negative symptoms in schizophrenics treated with neuroleptics. J Nerv Ment Dis 1987", pp.100~105, Hollister LE. Depression
22. Addington D, "Maticka-Tyndale E. Asessing dep-resion in schizophrenia", pp.22 39~44, the Calgary Depression Scale. Br J Psychiatry 193
23. Bartels SJ, "Drake RE. Depressive symptoms in schizophrenia", pp.198 467~483
24. "Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960", pp.56~62
25. Addington D, "Schisel B. A depression rating scale for schizophrenics. Schizophr Res 1990", pp.247~251
26. Addington D, "Joyce J. Relia-bility and validity of a depression rating scale for schizophre-nics. Schizophr Res 1992", pp.201~208
27. Fujii A, "Ohmori T. Psychometric properties of the Japanese version of the Calgary Depression Scale for Schizo-phrenics. J Nerv Ment Dis 200", pp.237~239
28. . Washington, "American Psychiatric Association. Diagnostic and Statistical Ma-nual of Mental Disorders" (1994)
29. Kaneda Y, "Depressive symptoms in chronic schizophrenia pati-ents: any differences betwen patients with and without a major depressive episode?", 18, pp.137~139 (2003)
30. Rupprecht R, "Schwarz W. Diferent reactivity of the hypothalamo-pituitary-gonadal-axis in depression and normal controls. Pharmacopsychiatry 1988", (der m), pp.438~439
31. Seidman SN, "Walsh BT. Testosterone and depression in aging men. Am J Geriatr Psychiatry 19"
32. Steiger A, "Holsboer F. Sleep EG and nocturnal secretion of testosterone and cortisol in patients with major endogenous depression during acute phase and after remission. J Psychiatr Res 191", pp.169~177
33. Sternbach H, "Age-associated testosterone decline in men: clini-cal issues for psychiatry", 155, pp.1310~1318 (1998)
34. Unden F, "Hypothalamic-pituitary-gonadal axis in major depressive di-sorders", pp.138~146
35. Vogel W, "Broverman DM. Roles of the gonadal steroid hormones in psychiatric depression in men and women. Prog Neuropsychopharmacol 1978", pp.487~503
36. Halbreich U, "Hormonal aspects of schizophrenias: an overview", 28(Suppl 2), pp.1~16 (2003)
37. Hausmann A, "Diferential diagnosis of de-pressed mod in patients with schizophrenia: a diagnostic algo-rithm based on a review", 106, pp.83~96 (2002)
38. Meltzer HY, "Le JC. The ratios of serotonin2 and dopamine2 afinities differentiate atypical and typical anti-psychotic drugs. Psychopharmacol Bul 1989", pp.390~392
39. Seeman P, "Antipsychotic drugs which elicit little or no parkinsonism bind more losely than dopamine to brain D2 receptors, yet occupy high levels of these receptors", 3, pp.123~134 (1998)
40. Cohen LJ, "data from a prospective community treatment study. Am J Psy-chiatry 1990", pp.602~607
41. Caldwell CB, "Gottesman II. Schizophrenia--a high-risk factor for suicide clues to risk reduction. Suicide Life Threat Behav 1992", pp.479~493
42. Haris EC, "Baraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 197", pp.205~28
43. Harkavy-Friedman JM, "Suicidal behavior in schizophre-18· Y. Kaneda nia: characteristics of individuals who had and had not attemp-ted suicide", 156, pp.1276~1278 (1999)
44. Mortensen PB, "Juel K. Mortality and causes of death in first ad-mitted schizophrenic patients. Br J Psychiatry 1993"
45. Wyat RJ, "An economic evalua-tion of schizophrenia--1991", 30, pp.196~205 (1995)
46. Meltzer HY, "et al. Clozapine treatment for suicidality in schizophrenia", pp.82~91
47. Kaneda Y, "Suicidal behavior before, during, and after the first year of psychosis in patients with schi-zophrenia and schizoaffective disorder", 13, pp.276~ (2004)
48. Meltzer HY, "Suicide and schizophrenia: clozapine and the Inter-SePT study. International Clozaril", Leponex Suicide Prevention Trial, 60 47~12 50
49. Cem Atbasoglu E, Schultz SK, Andreasen NC, "The relation-ship of akathisia with suicidality and depersonalization among patients with schizophrenia", 13, pp.336~341 (2001)
50. "Expert consensus panel for optimizing pharmacologic treatment of psychotic disorders. Expert consensus guideline series. Op-timizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 203", pp.64 2~12 97
51. Khan A, "Brown WA. Symptom reduc-tion and suicide risk among patients treated with placebo in antipsychotic clinical trials an analysis of the fod and drug administration database. Am J Psychiatry 201", pp.1449~1454
52. Nozaki S, "Suicide and atypical antipsychotic (in Japanese)", 5, pp.1429~1434 (2002)
53. Schwartz RC, "Does insight affect long-term impatient treatment outcome in chronic schizophrenia?", 38, pp.283~288 (1997)
54. Smith TE, "The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoafective disorder", 187, pp.102~108 (1999)
55. Cunningham Owens DG, "A randomized, controlled trial of a brief inter-ventional package for schizophrenic out-patients", 103, pp.362~369 (2001)
56. Amador XF, "Suicidal behavior in schizophrenia and its relationship to awareness of ilness", 153, pp.185~1188 (1996)
57. a repli-cation study. J Nerv Ment Dis 200, "Schwartz RC. Insight and suicidality in schizophrenia", pp.235~237

관련 논문AI추천